Diabetic Neuropathy Market Explore Future Growth 2018-2026 by Global Top Players – Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals

Coherent Market Insights has announced the addition of the “Diabetic Neuropathy Market Size Status and Forecast 2026”, The report classifies the global Diabetic Neuropathy Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Diabetic Neuropathy Speaker market, analyzes and researches the Diabetic Neuropathy Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Neuropathy is defined as the damaged caused to the nerves, and diabetic neuropathy refers to the nerve damages caused due to diabetes. Diabetes damages body nerves as a result of increased levels of blood glucose. Diabetic neuropathy is the most commonly found complication of diabetes.

Request a sample copy: https://www.coherentmarketinsights.com/insight/request-sample/213

Diabetic Neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. An estimated 50% of diabetic population suffers from diabetic neuropathy across the globe. Further, as per CDC estimates, 6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the U.S. Rise in aging population coupled with rise in prevalence of diabetes, the patient pool for diabetic neuropathy will increase significantly, in turn fueling growth of the diabetic neuropathy market.

Market Growth

The diabetic neuropathy market has been under continuous evolution from the past 5 years. There are generic drugs and specialty drugs including antidepressants and antispasmodics, as well to treat pain associated with the disorder. However, in 2011, there were an estimated 79 novel drugs in the clinical trial phase with Horizant (Gabapentin Enacarbil extended release) being one of the most effective drug. The pharmaceutical companies will continue the required geographic expansion and release novel drugs across major countries in different regions. Further, the growing awareness about diabetic neuropathy, increased healthcare spending and increase in pharmaceutical R&D spending will be important factors for growth in the diabetic neuropathy market.

Increasing prevalence of diabetes cases, growing, aging population, rise in healthcare expenditure for diabetes, growing awareness about diabetes and related nerve complications, and rise in R&D activities in drug discovery and developmemt are the key factors driving the global diabetic neuropathy market. However, high failure rate in clinical trials, stringent regulatory requirements, and longer approval time for drugs are some of the factors restraining the growth for global diabetic neuropathy market.

By Disorder

Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

By Treatment
Drugs
Analgesics
Topical
Capsaicin
Opioid
Morphine

NSAIDs (Non-steroidal Anti-inflammatory Drugs)
Ibuprofen
Naproxen
Anti-depressants

TCAs (Tricyclic Anti-depressants)
Amitriptyline
Imipramine

SNRIs (Selective Nor-epinephrine Reuptake Inhibitors)
Duloxetine

SSRIs (Selective Serotonin Reuptake Inhibitors)
Citalopram
Paroxetin
Anti-convulsant
Gabapentin
Pregabalin
Topiramate

Other Drugs
Radiotherapy
Physiotherapy

By Distribution Channel

Hospitals
Clinics
Pharmacy

What Information does this report contain?

-Historical data coverage: 2013 to 2017; Growth Projections: 2018 to 2026.
-Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
-6-7 year performance forecasts: major segments covering applications, top products and geographies.
-Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Asia Pacific region is fastest growing region with countries such as India and China showing lucrative growth. India has one of the highest rates of diabetes type 2 in the world and according to an independent research, by year 2030, an estimated 80 million people will be affected with diabetes type 2 in India. Additionally, the study concluded that the prevalence rate for diabetic neuropathy was 29% in the entire patient population. China has edged India and has a diabetes patient population of 110 million which is projected to reach 150 million by 2040, as per data published by WHO. Major pharmaceutical companies are now venturing into Asia pacific region and the market is poised to witness substantial growth in the region due to large patient population, less stringent regulatory scenario, increasing R&D investment, growth in clinical trials conducted and government funding for the disease treatment.

Else place an Inquire before Purchase “Diabetic Neuropathy Market Size, Status and Forecast 2026: https://www.coherentmarketinsights.com/insight/talk-to-analyst/213

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.